Together with 52 patient advocacy groups, we submitted a response to the U.S. Department of Health & Human Services (HHS) RFI on its Blueprint to Lower Drug Prices & Reduce OOP Costs on July 16, 2018. Our patients are our priority, and we want to be sure their needs are considered in future policy development.
Read our full letter to the Department of Health and Human Services online.
